June 10-12, 2012 | San Antonio, TX

ABOUT THE FORUM

The role of the Chief Financial Officer or Head of Finance from any life science organization is a highly dynamic and evolving position, with responsibilities and influence throughout the entire company, from R&D to manufacturing and commercialization. Today’s financial officer positions are not limited to accounting and reporting, but also focus on managing revenues across the organization, approving purchases, understanding pricing & reimbursement challenges, and how each will impact current and future revenue forecasting. The annual Life Science Finance Forum will address these challenges and more, through a three day networking and content driven program design by, and for, today’s progressive Finance executive.

Overall, the 3nd Annual Life Science Financial Forum will offer attendees an unrivaled opportunity for networking and knowledge sharing. Consistently lauded as a unique and effective use of time and resources, this program has become a mainstay for CFOs and finance executives seeking new strategies and methods for keeping their organizations at the forefront of the industry.

TOPICS TO INCLUDE:

• Recognizing Financial Opportunity in an Uncertain Economy
• Optimizing Finance’s Role Across the Life Science Industry to Amplify Business Performance
• Implementing a Corporate Governance System Conducive to the Needs of Internal and External Stakeholders
• Establishing Proactive Strategies to Prepare for Government Investigations
• Examining the Current Financial Implications of the Foreign Corrupt Practices Act (FCPA) on the Life Science Industry
• Understanding and Adapting to Modifications in Revenue Recognition Standards
• Exploring the Possible Convergence of the US GAAP and Global IFRS Standards
• Present & Future Impact of Healthcare Reform Throughout the Life Science Industry
• Healthcare Reform and the Implementation of the Medical Device Excise Tax
• Deciphering the Patient Protection and Affordable Care Act and the Pharmaceutical Excise Tax
• Bridging the Gap between Tax Executives & the Executive Board
• Overcoming Financial Challenges Caused by Evolving Reimbursement Rates & Policies
• Maximizing Funding Across the Life Science Industry through Traditional and Innovative Avenues
• Communicating Financial Objectives through an Optimization of Investor Relations
• Overcoming Initial Public Offering Challenges in Transitioning from Private to Public Company
• Overcoming the Financial Effect of Loss of Product Exclusivity
• The Financial Impact of Increased Government Regulation on Product Lifecycles
• Managing a Tightened R&D Budget without Damaging Innovation
• Modifying Financial Planning and Analysis (FP&A) Strategies in an Ever Changing Environment
• Analysis of M&A Activity in the Life Science Industry
• Financial Implications of Licensing Partnerships in an Increasingly Competitive Environment
• Maximizing Financial Returns on International Operations
• Improving Partnerships with Outside Firms to Maintain Financial Stability and Compliance
• Utilizing New Technologies to Create Substantial Company Cost Savings

Add to Calendar

KEY PRESENTERS TO INCLUDE:

Brett Foster
CFO
Vital Signs Devices, GE Healthcare

Derek Kosti
Senior Finance Director
Pfizer

Eric Elam
Director of Business Development
Stryker